PIVKA-II is a useful tool for diagnostic characterization of ultrasound ...
Protein induced by vitamin K absence-II (PIVKA-II) is a potential screening marker for hepatocellular carcinoma (HCC). Limited data are available about its utility in discriminating neoplastic from regenerative nodules at ultrasonography (US) evaluation in cirrhotic patients.
PIVAKAN 0.5%WV (PLAIN) INJECTION (20ML - myHealthbox
2022年8月11日 · PIVAKAN 0.5% PLAIN produces muscle relaxation in the lower limbs which lasts 3-4 hours, somewhat shorter than the duration of sensory blockade. PIVAKAN 0.5% PLAIN is slightly hyperbaric (compared to cerebrospinal fluid) at 20°C and slightly hypobaric at 37°C.
PIVKA-II serves as a potential biomarker that complements AFP …
PIVKA-II is a promising serum biomarker for the HCC diagnosis that can be used as a supplement for AFP. The combined diagnosis of the two markers greatly improved the diagnostic efficiency of HCC.
The clinical application of PIVKA‐II in hepatocellular carcinoma and ...
Multi‐center study showed the satisfactory diagnostic performance of PIVKA‐II in hepatocellular carcinoma. PIVKA‐II has excellent specificity in distinguishing benign liver diseases. The distribution of PIVKA‐II among chronic liver diseases. 1. INTRODUCTION.
Prothrombin induced by vitamin K absence-II (PIVKA-II), also known as des-γ-carboxyl prothrombin (DCP) has been linked to HCC especially in the early stages compared with non-HCC, especially hepatitis B virus (HBV) related HCC (Wang et al. 2017).
PIVKA-II serves as a potential biomarker that complements AFP ... - PubMed
2021年4月13日 · PIVKA-II is a promising serum biomarker for the HCC diagnosis that can be used as a supplement for AFP. The combined diagnosis of the two markers greatly improved the diagnostic efficiency of HCC. The PIVKA-II levels in HCC patients were widely associated with clinicopathological characteristics rep …
PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A ...
Results: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml.
Effectiveness of PIVKA-II in the detection of hepatocellular …
2017年9月1日 · Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is an efficient biomarker specific for hepatocellular carcinoma (HCC). Some researchers have proved that levels of PIVKA-II reflect HCC oncogenesis and progression. However, the effectiveness of PIVKA-II based on real-world clnical data has barely been studied.
Usefulness of PIVKA-II for monitoring after liver ... - Nature
2023年4月6日 · Serum PIVKA-II levels may play an important role in predicting disease severity. Furthermore, monitoring PIVKA-II levels in HCC transplant recipients reflects the tumor early recurrence after...
Pivakan 0.5%w/v (Plain) Injection (20ml/Vial) - farmakopedia.com
Pivakan 0.5%w/v (Plain) Injection (20ml/Vial) Drug Info Puchong, Selangor, Kuala Lumpur (KL), Malaysia Dealer, Supplier, Seller, Distributor , Farmakopedia is a health information site that aims to provide medical and health-related knowledge to …